ライフサイエンスコーパス: emtricitabine

1 istered topically or orally (with or without emtricitabine).

2 nofovir and 212.5 ng/mL (140.0 to 405.0) for emtricitabine.

3 y dose of tenofovir disoproxil fumarate plus emtricitabine.

4 osphates and triphosphates of lamivudine and emtricitabine.

5 oproxil fumarate, alone or coformulated with emtricitabine.

6 and/or concomitant use of lamivudine and/or emtricitabine.

7 than the regimen with efavirenz-tenofovir DF-emtricitabine.

8 bacavir-lamivudine but not with tenofovir DF-emtricitabine.

9 h zidovudine or tenofovir plus lamivudine or emtricitabine.

10 were TDF/emtricitabine (57%), lamivudine or emtricitabine (19%), or TDF monotherapy (13%).

11 The NRTIs emtricitabine [(-)-2,3'-dideoxy-5-fluoro-3'-thiacytidine

12 5 mg or dolutegravir 50 mg with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg, wi

13 ived darunavir 800 mg, ritonavir 100 mg, and emtricitabine 200 mg daily.

14 (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28

15 T in pregnancy (once-daily tenofovir 300 mg, emtricitabine 200 mg, and efavirenz 600 mg) and achievin

16 ning elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg (t

17 n of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg on

18 taining darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, w

19 , to receive coformulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or

20 al fixed-dose combination bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or

21 Subjects with VF added emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once dai

22 imen) or tenofovir (245 mg once per day) and emtricitabine (200 mg once per day; standard regimen).

23 f tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) and advised to take one tablet pe

24 d tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a def

25 ith atazanavir (300 mg), ritonavir (100 mg), emtricitabine (200 mg), and tenofovir (300 mg) daily.

26 ingle-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg

27 ablet regimen of either rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg

28 single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarat

29 ingle-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarat

30 n = 64) or a combination of TDF (300 mg) and emtricitabine (200 mg, n = 62) for 192 weeks.

31 , with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumara

32 Anti-HBV regimens were TDF/emtricitabine (57%), lamivudine or emtricitabine (19%),

33 efined as the combined GSS for lamivudine or emtricitabine, abacavir, zidovudine, stavudine, didanosi

34 bo plus the fixed-dose combination of 200 mg emtricitabine and 25 mg tenofovir alafenamide for 48 wee

35 essed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) und

36 gravir group] and 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir gr

37 udy drug to 98 (65 received bictegravir plus emtricitabine and tenofovir alafenamide and 33 received

38 INTERPRETATION: Bictegravir plus emtricitabine and tenofovir alafenamide and dolutegravir

39 tions-coformulated with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose

40 and safety of bictegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose

41 tenofovir alafenamide and dolutegravir plus emtricitabine and tenofovir alafenamide both showed high

42 One participant taking bictegravir plus emtricitabine and tenofovir alafenamide discontinued bec

43 ) of 65 participants in the bictegravir plus emtricitabine and tenofovir alafenamide group versus 22

44 rsus 22 (67%) of 33 in the dolutegravir plus emtricitabine and tenofovir alafenamide group.

45 lafenamide and 33 received dolutegravir plus emtricitabine and tenofovir alafenamide).

46 existing INSTI options with the backbone of emtricitabine and tenofovir alafenamide, might provide a

47 dolutegravir administered with coformulated emtricitabine and tenofovir alafenamide.

48 ily preexposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF

49 rEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF

50 egimen) or ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (proteas

51 n who has sex with men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 mo

52 Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highl

53 Pre-exposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used

54 an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil fumarate).

55 pe HIV-1 infection despite consistent use of emtricitabine and tenofovir disoproxil fumarate.

56 regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.

57 rEP programme with sexual event-based use of emtricitabine and tenofovir for MSM who had condomless a

58 ir (switch group) or continue the NNRTI plus emtricitabine and tenofovir regimen (no-switch group).

59 le alternative for patients on an NNRTI with emtricitabine and tenofovir regimen considering a regime

60 er mL for at least 6 months on an NNRTI plus emtricitabine and tenofovir regimen.

61 ory of virological failure, no resistance to emtricitabine and tenofovir, and creatinine clearance of

62 , and HIV-1 genotypes showing sensitivity to emtricitabine and tenofovir.

63 /lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third single or boosted drug, which

64 ough L-deoxycytidine analogs (lamivudine and emtricitabine) and L-thymidine (telbivudine) have been w

65 In subjects on optimal anti-HBV therapy (TDF/emtricitabine) and with undetectable HIV RNA, HBeAg, CD4

66 0 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/te

67 0 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide.

68 ine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293), and C (emtri

69 conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472

70 d to an ART regimen that included tenofovir, emtricitabine, and efavirenz for 48 weeks.

71 n to an ART regimen that included tenofovir, emtricitabine, and efavirenz for 48 weeks.

72 or ART (fixed-dose combination of tenofovir, emtricitabine, and efavirenz) regardless of CD4 cell cou

73 eive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either cobicistat-boosted elvitegravi

74 use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transmission

75 onavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir-ritonavir (tenofovir-based

76 demonstrate that a combination of tenofovir, emtricitabine, and raltegravir effectively suppresses pe

77 ch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (switch group) or continue

78 cipants to receive coformulated bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or cofo

79 TION: At 48 weeks, coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virolo

80 assigned and treated (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with ef

81 cacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as a potential

82 ingle-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with r

83 Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not requir

84 assigned to treatment (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose comb

85 INTERPRETATION: Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz,

86 patients (n=290 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0%

87 ) of 438 in participants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienc

88 The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently be

89 ose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-infected

90 ose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily

91 The elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was wel

92 Exposures to the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen were si

93 ss frequently in patients given bictegravir, emtricitabine, and tenofovir alafenamide than in those g

94 tudy drug were less common with bictegravir, emtricitabine, and tenofovir alafenamide than with dolut

95 emonstrating non-inferiority of bictegravir, emtricitabine, and tenofovir alafenamide to dolutegravir

96 gle-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continui

97 ose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was efficacious

98 INTERPRETATION: Switching to rilpivirine, emtricitabine, and tenofovir alafenamide was non-inferio

99 Bictegravir, emtricitabine, and tenofovir alafenamide was safe and we

100 The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and we

101 Exposures to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide were higher, bu

102 on of therapy with elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combin

103 d (1:1) to receive elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integr

104 Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofo

105 regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compare

106 (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at

107 HIV-1 RNA <50 copies per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at

108 pared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

109 e, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non

110 ed with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

111 mide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

112 ing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

113 Lamivudine, zidovudine, emtricitabine, and tenofovir had no effects.

114 Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir might be a useful regimen s

115 ch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their exi

116 Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir seems to be efficacious and

117 Lamivudine, abacavir, zidovudine, emtricitabine, and tenofovir significantly inhibited tel

118 1 genotype with sensitivity to elvitegravir, emtricitabine, and tenofovir.

119 en to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir.

120 mL or more, and susceptibility to efavirenz, emtricitabine, and tenofovir.

121 mL or more and susceptibility to atazanavir, emtricitabine, and tenofovir.

122 We investigated whether tenofovir and emtricitabine are excreted into breast milk and then abs

123 including coformulation with rilpivirine and emtricitabine, as initial and ongoing treatment for HIV-

124 3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricita

125 and EVGcobi, associated to tenofovir-DF and emtricitabine, behave similarly and achieve an undetecta

126 ples were collected to measure tenofovir and emtricitabine concentrations (a measure of adherence and

127 Tenofovir and emtricitabine concentrations were quantified using liqui

128 s high incidence population, daily tenofovir-emtricitabine conferred even higher protection against H

129 vir 800/100 mg in combination with tenofovir/emtricitabine daily.

130 h participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I (detectab

131 were studied (all paired with lamivudine or emtricitabine): efavirenz (EFV) plus zidovudine (AZT) (n

132 Authorized antiretrovirals were tenofovir, emtricitabine, efavirenz, atazanavir, and raltegravir.

133 For emtricitabine, FGT:plasma was significantly lower in par

134 ived RAL, tenofovir disoproxil fumarate, and emtricitabine for 72 weeks.

135 ted to advise the approval of oral tenofovir-emtricitabine for PrEP in high-risk populations.

136 Recent FDA approval of tenofovir-emtricitabine for prevention of human immunodeficiency v

137 PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV infection is rol

138 plus tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) (Complera((R))) and an extended rele

139 estigated whether the combination of TAF and emtricitabine (FTC) could prevent simian/human immunodef

140 initiate open-label ART with tenofovir (TDF)/emtricitabine (FTC) once/day plus either NVP (n = 249) o

141 n of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual a

142 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in hu

143 t r = 0.734; P < .001), as were hair TFV/DBS emtricitabine (FTC) triphosphate (TP) (r = 0.781; P < .0

144 th 36 (P < 0.001), while lamivudine (LAM) or emtricitabine (FTC) use remained steady (71.9%) and teno

145 with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (

146 with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (

147 is often coformulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering effect.

148 olled trial of daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfected African men and w

149 d, comparing 4 regimens: MVC alone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumar

150 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (

151 ither zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FTC), or lopinavir/ritonavir for either 7

152 receipt of tenofovir (TDF), coformulated TDF/emtricitabine (FTC), or placebo.

153 ted the adherence and safety of coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir di

154 n addition to tenofovir difumarate (TDF) and emtricitabine (FTC), the quad pill includes cobicistat (

155 on or after week 72 had the option of adding emtricitabine (FTC).

156 ivudine (3TC)/nevirapine (NVP) (n = 3), TDF/ emtricitabine (FTC)/NVP (n = 9), TDF/3TC/efavirenz (EFV)

157 ncer of atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)

158 decreases the prophylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

159 en TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FT

160 fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acqui

161 roxil fumarate (TDF), alone or combined with emtricitabine (FTC-TDF), compared with placebo.

162 f antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) provide little structural evid

163 triphosphates of lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) with four ternary complexes pe

164 g antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP), we structurally reveal the co

165 preexposure prophylaxis (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [T

166 were highest for the TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%;

167 HIV-infected women on ART (tenofovir [TFV], emtricitabine [FTC], and ritonavir-boosted atazanavir [A

168 r at the end of treatment with TDF (n552) or emtricitabine(FTC)/TDF (n57).

169 up and 76% of patients (47 of 62) in the TDF+emtricitabine group had levels of HBV DNA <69 IU/mL (P =

170 gimens containing tenofovir (with or without emtricitabine) has been demonstrated.

171 ovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-

172 Tenofovir/emtricitabine HIV prevention trials among women in Afric

173 formulated tenofovir disoproxil fumarate and emtricitabine in 2499 men who have sex with men (MSM) an

174 e daily (NtRTI-sparing regimen) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combinat

175 The inclusion of lamivudine or emtricitabine in cART did not influence the time to viro

176 mivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapine was a stron

177 steady-state concentrations of tenofovir and emtricitabine in infant plasma ingested via breastfeedin

178 the virological responses to lamivudine and emtricitabine in recommended cART.

179 ART) for HIV/HBV (tenofovir, lamivudine, and emtricitabine) in a large cohort encompassing heterosexu

180 onotherapy or a combination of tenofovir and emtricitabine) in HIV serodiscordant couples aged 18 yea

181 efavirenz/nevirapine, in 81% for lamivudine/emtricitabine, in 59% for etravirine/rilpivirine, in 27%

182 The use of emtricitabine instead of lamivudine as part of cART was

183 ological failure during therapy with RPV and emtricitabine is associated with the appearance of E138K

184 Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexposure prop

185 Although the combination of tenofovir and emtricitabine is the only PrEP agent that was studied an

186 mbination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency vi

187 f five antiviral drugs (abacavir, acyclovir, emtricitabine, lamivudine and zidovudine) via both bio-

188 Among studied drugs (efavirenz, tenofovir, emtricitabine, lamivudine, and indinavir), only efaviren

189 formulated tenofovir disoproxil fumarate and emtricitabine once a day (atazanavir group).

190 efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine once daily (EFV-TDF-FTC group).

191 os(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine) and with no re

192 daily, with investigator-selected tenofovir-emtricitabine or abacavir-lamivudine.

193 HIV-infected patients on EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFLD were ran

194 reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a nonnucleosi

195 (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine.

196 estigator-selected combination tenofovir and emtricitabine or combination abacavir and lamivudine bac

197 troviral therapy (ART) with either tenofovir-emtricitabine or lamivudine (tenofovir group) or zidovud

198 Despite sparse efficacy data, tenofovir-emtricitabine or tenofovir-lamivudine plus nevirapine is

199 tion with either oral tenofovir or tenofovir-emtricitabine, or daily tenofovir gel.

200 each with tenofovir disoproxil fumarate and emtricitabine orally once daily, for up to 96 weeks.

201 tonavir 100 mg twice daily and lamivudine or emtricitabine plus another nucleoside reverse transcript

202 were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavi

203 person-years) and 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 c

204 Preexposure prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TD

205 m a ritonavir-boosted protease inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofo

206 es received tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and wer

207 disoproxil fumarate relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP

208 :1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP

209 cal trial (HPTN 067/ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a re

210 andomised controlled trial of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compare

211 95% CI 0.06-0.37; p<0.0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (

212 ommendations for daily use of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in wome

213 daily oral tenofovir disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in

214 -daily oral tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimen

215 HIV-1 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not

216 tenofovir disoproxil fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but sh

217 a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1

218 ovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcripta

219 and therapy with the combination of TDF and emtricitabine provided better viral suppression than TDF

220 ated by hair concentrations of tenofovir and emtricitabine (ptrend=0.008).

221 revention strategies that also use tenofovir/emtricitabine, raising concerns regarding drug resistanc

222 e-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.

223 nofovir and 183.0 ng/mL (113.0 to 250.0) for emtricitabine, reflecting trough-to-peak breast milk con

224 ealed only an M184V mutation associated with emtricitabine resistance.

225 breast milk concentrations of tenofovir and emtricitabine (respective median trough-to-peak concentr

226 tion ratios of 1.0 for tenofovir and 0.8 for emtricitabine, respectively.

227 ceiving a daily combination of tenofovir and emtricitabine, suggest physicians offer PrEP to patients

228 or-associated resistance that led to reduced emtricitabine susceptibility.

229 f doses of tenofovir disoproxil fumarate and emtricitabine taken per week, as estimated by hair conce

230 ral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrE

231 ive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily.

232 ination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily.

233 ir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal g

234 daily tenofovir (TDF), combination tenofovir-emtricitabine (TDF-FTC), or matching placebo--and follow

235 umber of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) doses required to achieve and ma

236 worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for ad

237 h abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) in 1857 human immunodeficiency v

238 -based regimens with a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC)

239 The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r

240 zed equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r

241 zed to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r

242 vir-lamivudine (ABC/3TC) versus tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanav

243 nd no history of resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or tenofovir.

244 was non-inferior to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintain

245 enofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

246 ; screening genotypes showing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir; and

247 commend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral the

248 luated the safety and efficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-se

249 e short-term, open-label study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 5

250 tricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FT

251 itabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavire

252 xposure prophylaxis (PrEP) trial and whether emtricitabine/tenofovir (FTC/TDF) modified that associat

253 acebo-controlled trial of oral tenofovir and emtricitabine/tenofovir among HIV-uninfected members of

254 navir/ritonavir (400/100 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg)

255 arate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF

256 ared the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/T

257 ir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), i

258 In the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is

259 Daily preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is

260 Daily emtricitabine/tenofovir disoproxil fumarate is recommend

261 tigen-specific responses were independent of emtricitabine/tenofovir disoproxil fumarate use.

262 e BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

263 e/3TC had lost limb fat, and those receiving emtricitabine/tenofovir had gained it.

264 With emtricitabine/tenofovir, levels of HDL-C were increased,

265 y assigned to receive lamivudine/zidovudine, emtricitabine/tenofovir, or lopinavir/ritonavir for 7 or

266 2 months compared to PI-based regimens while emtricitabine/tenofovir/efavirenz was associated with re

267 MD between those receiving and not receiving emtricitabine/tenofovir/efavirenz were more pronounced a

268 or between those receiving and not receiving emtricitabine/tenofovir/efavirenz.

269 ed-glycerin (RG) 1% tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

270 mucosal tissue concentrations of tenofovir, emtricitabine, their active metabolites (tenofovir dipho

271 ng ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL) infusion

272 1 (HIV-1) infection consider lamivudine and emtricitabine to be interchangeable components in first-

273 fovir and 31.9 mug/kg (IQR 21.0 to 60.8) for emtricitabine, translating into a <0.01% and 0.5% relati

274 le sex (odds ratio = 7.05; P = .002) and TDF+emtricitabine treatment (odds ratio = 3.9; P = .01) were

275 tabolites (tenofovir diphosphate [TFVdp] and emtricitabine triphosphate [FTCtp], respectively), and c

276 PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada) has demonstrated efficacy in pla

277 Although lamivudine and emtricitabine, two L-deoxycytidine analogs, have been wi

278 lure at week 240 using lamivudine instead of emtricitabine was 2.35 (95% CI, 1.61-3.42) with efaviren

279 adherence, and tenofovir disoproxil fumarate/emtricitabine was associated with higher adherence.

280 s unquantifiable in 46/49 samples (94%), but emtricitabine was detectable in 47/49 (96%) (median [IQR

281 TDF/emtricitabine was less likely to be associated with dete

282 Tenofovir/emtricitabine was superior to other anti-HBV regimens in

283 rt taking daily oral co-formulated tenofovir/emtricitabine, we examined the prevalence and duration o

284 fant plasma concentrations for tenofovir and emtricitabine were 12,500 and >200-fold lower than the r

285 The virological responses to lamivudine and emtricitabine were compared by multivariable adjusted lo

286 ssigned (1:1) to switch to fixed-dose 200 mg emtricitabine with 10 mg or 25 mg tenofovir alafenamide

287 tenofovir alafenamide or to continue 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil

288 g an antiretroviral regimen of tenofovir and emtricitabine with efavirenz, rilpivirine, or raltegravi

289 e virological failure at week 48 compared to emtricitabine with efavirenz/tenofovir (10.8% vs 3.6%; a

290 esistance (N = 4740) initiated lamivudine or emtricitabine with efavirenz/tenofovir or nevirapine/ten

291 With its safety advantages, fixed-dose emtricitabine with tenofovir alafenamide has the potenti

292 afety and efficacy of fixed-dose combination emtricitabine with tenofovir alafenamide in patients swi

293 tabine with tenofovir disoproxil fumarate to emtricitabine with tenofovir alafenamide, high rates of

294 Emtricitabine with tenofovir disoproxil fumarate is a st

295 In patients switching from emtricitabine with tenofovir disoproxil fumarate to emtr

296 ofovir alafenamide in patients switched from emtricitabine with tenofovir disoproxil fumarate.

297 g regimens containing fixed-dose combination emtricitabine with tenofovir disoproxil fumartate from 7

298 , tenofovir, or abacavir, plus lamivudine or emtricitabine) with either efavirenz or nevirapine.

299 oval mechanism for abacavir, zidovudine, and emtricitabine, with half-lives (t1/2,photo) in wetland w

300 to-2-week postpartum "tail" of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine